title: Immunotherapy in Lung Cancer.
abstract: The treatment of patients with good performance status and advanced stage non-small cell lung cancer has been based on the use of first-line platinum-based doublet and second-line docetaxel. Immunotherapy represents a new therapeutic approach with the potential for prolonged benefit. Although the vaccines studied have not shown benefit in patients with non-small cell lung cancer, immune checkpoint inhibitors against the PD-1/PD-L1 axis showed increased overall survival compared with docetaxel in randomized clinical trials, which led to the approval of nivolumab and pembrolizumab. Because only a minority of patients benefit from this class of drugs, there has been an intense search for biomarkers.
authors.affiliation: Division of Oncology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8056, St Louis, MO 63110, USA.
authors.forename: Lingling
authors.initials: L
authors.lastname: Du
authors.affiliation: Thoracic Oncology Research Program, Yale Comprehensive Cancer Center, Yale School of Medicine, 333 Cedar Street, WWW221, New Haven, CT 06520-8028, USA.
authors.forename: Roy S
authors.initials: RS
authors.lastname: Herbst
authors.affiliation: Division of Oncology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8056, St Louis, MO 63110, USA. Electronic address: dmorgens@dom.wustl.edu.
authors.forename: Daniel
authors.initials: D
authors.lastname: Morgensztern
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors / Q000378:metabolism; D018572:Disease-Free Survival; D000077143:Docetaxel; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000378:metabolism / Q000401:mortality / Q000628:therapy*; D009363:Neoplasm Proteins / Q000627:therapeutic use; D000077594:Nivolumab; D017671:Platinum Compounds / Q000627:therapeutic use; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors / Q000378:metabolism; D015996:Survival Rate; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D009363:Neoplasm Proteins; C105992:PDCD1 protein, human; D017671:Platinum Compounds; D061026:Programmed Cell Death 1 Receptor; D043823:Taxoids; D000077143:Docetaxel; D000077594:Nivolumab; C582435:pembrolizumab
keywords: Immune checkpoint inhibitors; Non–small cell lung cancer; PD-L1; Vaccines